X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

T Cells Are Fruitful In Thwarting-Off Chronic Infections

Content Team by Content Team
10th March 2023
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

In cases when the body is subjected to cancer as well as chronic infections, cytotoxic T immune cells happen to be vital in defining the immune system. Abnormal as well as infected cells need to be eradicated in no time so as to limit the damage to the body, which is what T cells get to do.

The researchers from the University of Basel were looking to understand as to how these cells could help in fighting the chronic infections. Professor Daniel Pinschewer, from the department of biomedicine at the University of Basel, went on to lead an international research team in order to study cytotoxic T cells. The inference of the study shall help in accelerating the therapy development as well as vaccination strategies.

These T cells can go on to become specialised in two distinct ways: either they can become sprinters or marathon runners. That said, the latter can also convert into sprinters at any given point in time so as to root out the infection, as per Professor Pinschewer.

When a patient goes on to suffer from a chronic infection, T cells get activated, thereby making a strong inflammatory response take place simultaneously. This reaction goes on to shock the T cells into a position of brisk activity, which means that they can only go on to remove the infected cells in the short term. As per Prof. Pinschewer, if all the T cells went on to behave that way, then the immune defence could break down in no time. The scientists studied how the immune system can offer enough T cells against chronic infections over longer periods of time, even if there is such a response. It was found out that interleukin-33, or IL-33 protein, happens to be an essential part of the entire process. It in fact, acts as a biological marker that helps the T cells stay active for a longer period of time. IL-33 dwarfs the shock of the inflammation, as per Dr. Friederike Marx, who is one of the lead authors of the study. Il-33 also helps T cells multiply, which helps produce more long-lasting cells to fight the infection. Because of IL-33, there happen to be enough cytotoxic cells that help in the long haul and can very well pull off a final sprint even after a marathon.

Scientists believe that their inferences can enhance the chronic infections treatment like hepatitis C. It is in fact possible that IL-33 can be administered to chronic infection patients so as to support a response that results in immune response being effective. The researchers have also gone on to hypothesise that IL-33 can be used to elevate cancer immunotherapy. They are of an understanding that the protein could help T cells give out efficient as well as long-lasting and effective attacks against the tumour cells.

Previous Post

Randomness Drives Tumour Cells Response To Chemotherapy

Next Post

Temperature Stable TB Vaccine Gives Out Immune Response

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Temperature Stable TB Vaccine Gives Out Immune Response

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In